АДАПТИВНЫЙ Т-КЛЕТОЧНЫЙ ОТВЕТ В ПАТОГЕНЕЗЕ ВИРУСНОЙ ИНФЕКЦИИ, ОБУСЛОВЛЕННОЙ ВИРУСОМ ГЕПАТИТА С
https://doi.org/10.15789/1563-0625-2016-4-309-316
Аннотация
Вирусный гепатит С, будучи наиболее частой причиной поражения печени, представляет глобальную проблему, поскольку характеризуется широкой распространенностью, высокими показателями хронизации и значительно повышает риск возникновения цирроза печени и гепатоцеллюлярной карциномы. Многочисленными исследованиями показано, что ключевую роль в патогенезе и исходе инфекции, обусловленной вирусом гепатита С, играют антиген-специфические CD4+ и CD8+T-клетки. Развитие сильного устойчивого и мультиэпитопного Т-клеточного ответа приводит к элиминации вируса, тогда как несостоятельность адаптивного Т-клеточного ответа ассоциируется с персистенцией вируса. В настоящем обзоре приводятся данные о патогенетической значимости Т-клеточного ответа в элиминации вируса, вирусной персистенции и развитии гепатита, а также обсуждаются возможные механизмы несостоятельности Т-клеточного ответа при хронической инфекции.
Об авторах
Е. А. Олейник
ФГБНУ «Научно-исследовательский институт фундаментальной и клинической иммунологии»
Россия
Россия
аспирант лаборатории клеточной иммунотерапии,
630099, г. Новосибирск, Ядринцевская ул., 14,
ct_lab@mail.ru
О. Ю. Леплина
ФГБНУ «Научно-исследовательский институт фундаментальной и клинической иммунологии»
Россия
д.м.н., ведущий научный сотрудник лаборатории клеточной иммунотерапии
Россия
д.м.н., ведущий научный сотрудник лаборатории клеточной иммунотерапии
А. А. Останин
ФГБНУ «Научно-исследовательский институт фундаментальной и клинической иммунологии»
Россия
д.м.н., профессор, главный научный сотрудник лаборатории клеточной иммунотерапии
Россия
д.м.н., профессор, главный научный сотрудник лаборатории клеточной иммунотерапии
Н. М. Старостина
ФГБНУ «Научно-исследовательский институт фундаментальной и клинической иммунологии»
Россия
заслуженный врач РФ, к.м.н., заведующая отделением иммунологии Клиники иммунопатологии
Россия
заслуженный врач РФ, к.м.н., заведующая отделением иммунологии Клиники иммунопатологии
Е. Р. Черных
ФГБНУ «Научно-исследовательский институт фундаментальной и клинической иммунологии»
Россия
д.м.н., профессор, член-корр. РАН, заведующая лабораторией клеточной иммунотерапии
Россия
д.м.н., профессор, член-корр. РАН, заведующая лабораторией клеточной иммунотерапии
Список литературы
1. Alatrakchi N., Graham C.S., van der Vliet H.J., Sherman K.E., Exley M.A., Koziel M.J. Hepatitis C virus (HCV)-specific CD81 cells produce transforming growth factor beta that can suppress HCV-specific T-cell responses. J. Virol., 2007, Vol. 81, no. 11, pp. 5882-5892.
2. Apolinario A., Majano P.L., Lorente R., Núñez O., Clemente G., García-Monzón C. Gene expression profile of T-cell-specific chemokines in human hepatocyte-derived cells: evidence for a synergistic inducer effect of cytokines and hepatitis C virus proteins. J. Viral Hepat., 2005, Vol. 12, no. 1, рр. 27-37.
3. Bartenschlager R., Penin F., LohmannV., André P. Assembly of infectious hepatitis C virus particles. Trendsin Microbiology., 2011, Vol. 19, no. 2, pp. 95-103.
4. Badr G., Bédard N., Abdel-Hakeem M.S., Trautmann L., Willems B., Villeneuve J.P., Haddad E.K., Sékaly R.P., Bruneau J., Shoukry N.H. Early interferon therapy for hepatitis C virus infection rescues polyfunctional, long-lived CD8+ memory T cells. J. Virol., 2008, Vol. 82, no. 20, pp. 10017-10031.
5. Beaumont E., Roch E., Chopin L., Roingeard P. Hepatitis C Virus E1 and E2 Proteins Used as Separate Immunogens Induce Neutralizing Antibodies with Additive Properties. PLoS One., 2016, Vol. 11, no. 3, e0151626.
6. Bengsch B., Seigel B., Ruhl M., Timm J., Kuntz M., Blum H.E., Pircher H., Thimme R. Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD81 T cells is linked to antigen recognition and T cell differentiation. PLoS Pathog., 2010, Vol. 6, no. 6, e1000947.
7. Behrens S., Tomei L., Francesco R. Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. EMBO J., 1996, Vol. 15, no. 1, pp. 12-22.
8. Boettler T., Spangenberg H.C., Neumann-Haefelin C., Panther E., Urbani S., Ferrari C., Blum H.E., von Weizsäcker F., Thimme R. T cells with a CD4+CD25+ regulatory phenotype suppress in vitro proliferation of virusspecific CD8+ T cells during chronic hepatitis C virus infection. J. Virol., 2005, Vol. 79, no. 12, pp. 7860-7786.
9. Bolacchi F., Sinistro A., Ciaprini C., Demin F., Capozzi M., Carducci F.C., Drapeau C.M.J., Rocchi G., BergaminiIncreased A. Hepatitis C virus (HCV)-specific CD41CD251 regulatory T lymphocytes and reduced HCVspecific CD41 T cell response in HCV-infected patients with normal versus abnormal alanine aminotransferase levels. Clin. Exp. Immunol., 2006, Vol. 144, no. 2, pp. 188-196.
10. Bowen D.G., Zen M., Holz L., Davis T., Geoffrey W. McCaughan, Bertolino P. The site of primary T cell activation is a determinant of the balance between intrahepatic tolerance and immunity. J. Clin. Invest., 2004, Vol. 114, no. 5, pp. 701-712.
11. Bukh J., Miller R.H., Purcell R.H. Sequence analysis of the core gene of 14 hepatitis C virus genotypes. Proc. Natl. Acad. Sci USA., 1994, Vol. 91, no. 17, pp. 8239-8243.
12. Cox A.L., Mosbruger T., Lauer G.M., Pardoll D., Thomas D.L., Ray S.C. Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. Hepatology, 2005, Vol. 42, no. 1, pp. 104-112.
13. Dolganiuc A., Oak S., Kodys K., Golenbock D.T., Finberg R.W., Kurt-Jones E., Szabo G. Hepatitis C core and nonstructural 3 proteins trigger toll-like receptor 2-mediated pathways and inflammatory activation. Gastroenterology, 2004, Vol. 127, no. 5, pp. 1513-1524.
14. Dustin L.B., Rice C.M. Flying under the radar: the immunobiology of hepatitis C. Annu Rev. Immunol., 2007, Vol. 25, pp. 71-99.
15. Farci P., Alter H.J., Shimoda A., Govindarajan S., Cheung L.C., Melpolder J.C., Sacher R.A., Shih J.W., Purcell R.H. Hepatitis C virus-associated fulminant hepatic failure. N. Engl. J. Med., 1996, Vol. 335, no. 9, pp. 631-634.
16. Flynn J.K., Dore G.J., Hellard M., Yeung B., Rawlinson W.D., White P.A., Kaldor J.M., Lloyd A.R., Ffrench R.A., ATAHC Study Group. Early IL-10 predominant responses are associated with progression to chronic hepatitis C virus infection in injecting drug users. J. Viral Hepat., 2010, Vol. 18, no. 8, pp. 549-561.
17. Friedman S.L. Liver fibrosis – from bench to bedside. J. Hepatol., 2003, Vol. 38, Suppl. l, pp. 38-53.
18. Golden-Mason L., Palmer B.E., Kassam N., Townshend-Bulson L., Livingston S., McMahon B.J., Castelblanco N., Kuchroo V., Gretch D.R., Rosen H.R. Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD41 and CD81 T cells. J. Virol., 2009, Vol. 83, no. 18, pp. 9122-9130.
19. Golden-Mason L., Palmer B., Klarquist J., Mengshol J.A., Castelblanco N., Rosen H.R. Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction. J. Virol., 2007, Vol. 81, no. 17, pp. 9249-9258.
20. Grakoui A., Shoukry N.H., Woollard D.J., Han J.H., Hanson H.L., Ghrayeb J., Murthy K.K., Rice C.M., Walker C.M. HCV persistence and immune evasion in the absence of memory T cell help. Science, 2003, Vol. 302, no. 5645, pp. 659-662.
21. Gruber A., Lundberg L.G., Bjorkholm M. Reactivation of chronic hepatitis C after withdrawal of immunosuppressive therapy. J. Intern. Med., 1993, Vol. 234, no. 2, pp. 223-225.
22. Hashempoor T., Bamdad T., Merat S., Janzamin E., Nemati L., Jabbari H., Sharifi A.H., Zamini H. Expansion of CD4+ CD25+ FoxP3+ regulatory T cells in chronic hepatitis C virus infection. Iran J. Immunol., 2010, Vol. 7, no. 3, pp. 177-185.
23. Jo J., Aichele U., Kersting N., Klein R., Aichele P., Bisse E., Sewell A.K., Blum H.E., Bartenschlager R., Lohmann V., Thimme R. Analysis of CD8+ T-cell-mediated inhibition of hepatitis C virus replication using a novel immunological model. Gastroenterology, 2009, Vol. 136, no. 4, pp. 1391-1401.
24. Kared H., Fabre T., Bedard N., Bruneau J., Shoukry N.H. Galectin-9 and IL-21 mediate cross-regulation between Th17 and Treg cells during acute hepatitis C. PLoS Pathog., 2013, Vol. 9, e1003422.
25. Kim A.Y., Kuntzen T., Timm J., Nolan B.E., Baca M.A., Reyor L.L., Berical A.C., Feller A.J., Johnson K.L., Schulze zur Wiesch J., Robbins G.K., Chung R.T., Walker B.D., Carrington M., Allen T.M., Lauer GM. Spontaneous control of HCV is associated with expression of HLA-B*57 and preservation of targeted epitopes. Gastroenterology, 2011, Vol. 140, no. 2, pp. 686-696.
26. Kittlesen D.J., Chianese-Bullock K.A., Yao Z.Q., Braciale T.J., Hahn Y.S. Interaction between complement receptor gC1qR and hepatitis C virus core protein inhibits T-lymphocyte proliferation. J. Clin. Invest., 2000, Vol. 106, no. 10, pp. 1239-1249.
27. Klenerman P, Thimme R. T cell responses in hepatitis C: the good, the bad and the unconventional. Gut., 2012, Vol. 61, no. 8, pp. 1226-1234.
28. Komatsu H., Lauer G., Pybus O.G., Ouchi K., Wong D., Ward S., Walker B., Klenerman P. Do antiviral CD8+ T cells select hepatitis C virus escape mutants? Analysis in diverse epitopes targeted by human intrahepatic CD8+ T lymphocytes. J. Viral Hepat., 2006, Vol. 13, no. 2, pp. 121-130.
29. Kuiken C., Mizokami M., Deleage G., Yusim K., Penin F., Shin-I T., Charavay C., Tao N., Crisan D., Grando D., Dalwani A., Geourjon C., Agrawal A., Combet C. Hepatitis C databases, principles and utility to researchers. Hepatology, 2006, Vol. 43, no. 5, pp. 1157-1165.
30. Larrubia J.R., Calvino M., Benito S., Sanz-de-Villalobos E., Perna C., Pérez-Hornedo J., González-Mateos F., García-Garzón S., Bienvenido A., Parra T. The role of CCR5/CXCR3 expressing CD8+ cells in liver damage and viral control during persistent hepatitis C virus infection. J. Hepatol., 2007, Vol. 47, no. 5, pp. 632-641.
31. Larrubia J.R., Lokhande M.U., García-Garzón S., Miquel J., González-Praetorius A., Parra-Cid T., Sanz-deVillalobos E. Persistent hepatitis C virus (HCV) infection impairs HCV-specific cytotoxic T cell reactivity through Mcl-1/Bim imbalance due to CD127 down-regulation. J. Viral Hepat., 2013, Vol. 20, no. 2, pp. 85-94.
32. Larrubia J.R., Lokhande M.U., García-Garzón S., Miquel J., Subirá D., Sanz-de-Villalobos E. Role of T cell death in maintaining immune tolerance during persistent viral hepatitis. World J. Gastroenterol., 2013, Vol. 19, no. 12, pp. 1877-1889.
33. Lechner F., Wong D.K., Dunbar P.R., Chapman R., Chung R.T., Dohrenwend P., Robbins G., Phillips R., Klenerman P., Walker B.D. Analysis of successful immune responses in persons infected with hepatitis C virus. J. Exp. Med., 2000, Vol. 191, no. 9, pp. 1499-1512.
34. Liaw Y.F., Lee C.S., Tsai S.L., Liaw B.W., Chen T.C., Sheen I.S., Chu C.M. T-cell-mediated autologous hepatocytotoxicity in patients with chronic hepatitis C virus infection. Hepatology, 1995, Vol. 22, no. 5, pp. 1368-1373.
35. Liu S., Yang W., Shen L., Turner J.R., Coyne CB., Wang T. Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection. J. Virol., 2009, Vol. 83, no. 4. pp. 2011-2014.
36. Manns M.P., Wedemeyer H., Cornberg M. Treating viral hepatitis C: efficacy, sideeffects, andcomplications. Gut., 2006, Vol. 55, no. 9, pp. 1350-1359.
37. McKiernan S.M., Hagan R., Curry M., McDonald G.S., Kelly A., Nolan N., Walsh A., Hegarty J., Lawlor E., Kelleher D. Distinct MHC class I and II alleles areassociated with hepatitis C viral clearance, originating from a single source. Hepatology, 2004, Vol. 40, no. 1, pp. 108-114.
38. Miroux C., Vausselin T., Delhem N.. Regulatory T cells in HBV and HCV liver diseases: implication of regulatory T lymphocytes in the control of immune response. Expert Opin. Biol. Ther., 2010, Vol. 10, no. 11, pp. 1563-1572.
39. Missale G., Bertoni R., Lamonaca V., Valli A., Massari M., Mori C., Rumi M.G., Houghton M., Fiaccadori F., Ferrari C. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J. Clin Invest., 1996, Vol. 98, no. 3, pp. 706-714.
40. Mohd Hanafiah K., Groeger J., Flaxman A.D., Wiersma S.T. Global epidemiology of hepatitis C virus infection: New estimates of agespecific antibody to HCV seroprevalence. Hepatology, 2013, Vol. 57, no. 4, pp. 1333-1334.
41. Moradpour D., Penin F., Rice C.M. Replication of hepatitis C virus. Nat. Rev. Microbiol., 2007, Vol. 5, no. 6, pp. 453-463.
42. Nakamoto N., Cho H., Shaked A., Olthoff K., Valiga M.E., Kaminski M., Gostick E., Price D.A., Freeman G.J., Wherry E.J., Kyong-Mi Chang1. Synergistic Reversal of Intrahepatic HCV-Specific CD8 T Cell Exhaustion by Combined PD-1/CTLA-4 Blockade. PLoS Pathog., 2009, Vol. 5, no. 2, e1000313.
43. Park S.-H., Veerapu N.S., Shin E.-C., Biancotto A., McCoy J.P., Capone S., Rehermann A.F.B. Sub infectious hepatitis C virus exposures suppress T cell responses against subsequent acute infection. Nat. Med., 2013, Vol. 19, no. 12, pp. 1638-1642.
44. Penna A., Missale G., Lamonaca V., Pilli M., Mori C., Zanelli P., Cavalli A., Elia G., Ferrari C. Intrahepatic and circulating HLA class II-restricted, hepatitis C virus-specific T cells: functional characterization in patients with chronic hepatitis C. Hepatology, 2002, Vol. 35, no. 5, pp. 1225-1236.
45. Pillarisetty V.G., Shah A.B., Miller G., Bleier J.I., DeMatteo R.P. Liver dendritic cells are less immunogenic than spleen dendritic cells because of differences in subtype composition. J. Immunol., 2004, Vol. 172, no. 2, pp. 1009-1017.
46. Rosen H.R. Emerging concepts in immunity to hepatitis C virus infection. J. Clin. Invest., 2013, Vol. 123, no. 10, pp. 4121-4130.
47. Sarobe P., Lasarte J.J., Casares N., López-Díaz de Cerio A., Baixeras E., Labarga P., García N., BorrásCuesta F., Prieto J. Abnormal priming of CD4(+) T cells by dendritic cells expressing hepatitis C virus core and E1 proteins. J. Virol., 2002, Vol. 76, no. 10, pp. 5062-5070.
48. Schulze Zur Wiesch J., Ciuffreda D., Lewis-Ximenez L., Kasprowicz V., Nolan B.E., Streeck H., Aneja J., Reyor L.L., Allen T.M., Lohse A.W., McGovern B., Chung R.T., Kwok W.W., Kim A.Y., Lauer G.M. Broadly directed virusspecificCD4+T cell responses are primed during acute hepatitis C infection, butrapidly disappear from human blood with viral persistence. J. Exp. Med., 2012, Vol. 209, no. 1, pp. 61-75.
49. Semmo N., Day C.L., Ward S.M., Lucas M,, Harcourt G., Loughry A., Klenerman P. Preferential loss of IL-2-secreting CD41 T helper cells in chronic HCV infection. Hepatology, 2005, Vol. 41, no. 5, pp. 1019-1028.
50. Spirengers D., van der Molen R.G., Kusters J.G., Kwekkeboom J., van der Laan L.J., Niesters H.G., Kuipers E.J., De Man R.A., Schalm S.W., Janssen H.L. Flow cytometry of fine-needle-aspiration biopsies: a new method to monitor the intrahepatic immunological environment in chronic viral hepatitis. J. Viral Hepat., 2005, Vol. 12, no. 5, pp. 507-512.
51. Stelekati E., Shin H., Doering T.A., Dolfi D.V., Ziegler C.G., Beiting D.P., Dawson L., Liboon J., Wolski D., Ali M.A., Katsikis P.D., Shen H., Roos D.S., Haining W.N., Lauer G.M., Wherry E.J. Bystander chronic infection negatively impacts development of CD8(+) T cell memory. Immunity, 2014, Vol. 40, no. 5, pp. 801-813.
52. Takaki A., Wiese M., Maertens G., Depla E., Seifert U., Liebetrau A., Miller J.L., Manns M.P., Rehermann B. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat. Med., 2000, Vol. 6, no. 5, pp. 578-582.
53. Tester I., Smyk-Pearson S., Wang P., Wertheimer A., Yao E., Lewinsohn D.M., Tavis J.E., Rosen H.R. Immune evasion versus recovery after acute hepatitis C virus infection from a shared source. J. Exp. Med., 2005, Vol. 201, no. 11, pp. 1725-1731.
54. Thimme R., Binder M., Bartenschlager R. Failure of innate and adaptive immune responses in controlling hepatitis C virus infection. FEMS Microbiol. Rev., 2012, Vol. 36, no. 3, pp. 663-683.
55. Thimme R., Bukh J., Spangenberg H.C., Wieland S., Pemberton J., Steiger C., Govindarajan S., Purcell R.H., Chisari F.V. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc. Natl. Acad. Sci USA, 2002, Vol. 99, no. 24, pp. 15661-15668.
56. Thimme R., Oldach D., Chang K.M., Steiger C., Ray S.C., Chisari F.V. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J. Exp. Med., 2001, Vol. 194, no. 10, pp. 1395-1406.
57. Urbani S., Amadei B., Fisicaro P., Tola D., Orlandini A., Sacchelli L., Mori C., Missale G., Ferrari C. Outcome of acute hepatitis C is related to virus-specific CD4 function and maturation of antiviral memory CD8 responses. Hepatology, 2006, Vol. 44, no. 1, pp. 126-139.
58. Waggoner S.N., Hall C.H., Hahn Y.S. HCV core protein interaction with gC1q receptor inhibits Th1 differentiation of CD4+ T cells via suppression of dendritic cell IL-12 production. J. Leukoc. Biol., 2007, Vol. 82, no. 6, pp. 1407-1419.
59. Wedemeyer H., He X.S., Nascimbeni M., Davis A.R., Greenberg H.B., Hoofnagle J.H., Liang T.J., Alter H., Rehermann B. Impaired effector function of hepatitis C virus specific CD8+ T cells in chronic hepatitis C virus infection. J. Immunol., 2002, Vol. 169, no. 6, pp. 3447-3458.
60. Wilby K.J., Partovi N., Ford J.A., Greanya E., Yoshida E.M. Review of boceprevir and telaprevir for the treatment of chronic hepatitis C. Can. J. Gastroenterol., 2012, Vol. 26, no. 4, pp. 205-210.
61. World Health Organization. Hepatitis C: Fact sheet NO164. 2015. Available from: http://www.who.int/mediacentre/factsheets/fs164/en/.
62. You Q., Cheng L., Kedl R.M., Ju C. Mechanism of T cell tolerance induction by murine hepatic Kupffer cells. Hepatology, 2008, Vol. 48, no. 3, pp. 978-990.
63. Zhai N., Chi X., Li T., Song H., Li H., Jin X., CrispeI N., Su L, Niu J., Tu Z. Hepatitis C virus core protein triggers expansion and activation of CD4(+) CD25(+) regulatory T cells in chronic hepatitis C patients. Cell Mol. Immunol., 2015, Vol. 12, no. 6, pp. 743-749.
64. Zoulim F., Chevallier M., Maynard M., Trepo C. Clinical consequences of hepatitis C virus infection. Rev. Med. Virol., 2003, Vol. 13, no. 1, pp. 57-68.
Рецензия
Для цитирования:
Олейник Е.А., Леплина О.Ю., Останин А.А., Старостина Н.М., Черных Е.Р. АДАПТИВНЫЙ Т-КЛЕТОЧНЫЙ ОТВЕТ В ПАТОГЕНЕЗЕ ВИРУСНОЙ ИНФЕКЦИИ, ОБУСЛОВЛЕННОЙ ВИРУСОМ ГЕПАТИТА С. Медицинская иммунология. 2016;18(4):309-316. https://doi.org/10.15789/1563-0625-2016-4-309-316
For citation:
Oleynik E.A., Leplina O.Yu., Ostanin A.A., Starostina N.M., Chernykh E.R. ADAPTIVE T-CELL RESPONSE IN PATHOGENESIS OF HEPATITIS C INFECTION. Medical Immunology (Russia). 2016;18(4):309-316. (In Russ.) https://doi.org/10.15789/1563-0625-2016-4-309-316
Просмотров:
1217
Послать статью по эл. почте 